These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36310398)

  • 1. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
    Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
    Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
    Wieboldt R; Sandholzer M; Carlini E; Lin CW; Börsch A; Zingg A; Lardinois D; Herzig P; Don L; Zippelius A; Läubli H; Mantuano NR
    Cell Mol Immunol; 2024 May; 21(5):495-509. PubMed ID: 38448555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells.
    Wang Z; Geng Z; Shao W; Liu E; Zhang J; Tang J; Wang P; Sun X; Xiao L; Xu W; Zhang Y; Cui H; Zhang L; Yang X; Chang X; Qiu X
    Cell Mol Immunol; 2020 Nov; 17(11):1148-1162. PubMed ID: 31754235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
    van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
    Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tools to study and target the Siglec-sialic acid axis in cancer.
    Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
    FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialic Acid-Siglec-E Interactions During
    Mukherjee K; Khatua B; Mandal C
    Front Immunol; 2020; 11():332. PubMed ID: 32184783
    [No Abstract]   [Full Text] [Related]  

  • 8. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
    Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
    Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sialylation pattern in lung epithelial cell line and Siglecs expression in monocytic THP-1 cells as cellular indicators of cigarette smoke - induced pathology in vitro.
    Wielgat P; Trofimiuk E; Czarnomysy R; Holownia A; Braszko JJ
    Exp Lung Res; 2018 Apr; 44(3):167-177. PubMed ID: 29781747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
    Bärenwaldt A; Läubli H
    Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
    [No Abstract]   [Full Text] [Related]  

  • 11. Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity.
    Huang J; Li M; Mei B; Li J; Zhu Y; Guo Q; Huang J; Zhang G
    J Transl Med; 2022 Oct; 20(1):496. PubMed ID: 36316782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ligand interactions of B cell Siglecs are involved in the prevention of autoimmunity to sialylated self-antigens and in the quality control of signaling-competent B cells.
    Tsubata T
    Int Immunol; 2023 Oct; 35(10):461-473. PubMed ID: 37504378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
    Benmerzoug S; Chevalier MF; Verardo M; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
    Eur Urol Focus; 2022 May; 8(3):748-751. PubMed ID: 34147404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Analysis of Siglec Ligands by Flow Cytometry.
    Chang LY; Sridharan D; Angata T
    Curr Protoc; 2023 Dec; 3(12):e949. PubMed ID: 38050649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
    van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
    Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
    Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
    Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
    Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
    Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway.
    Grabenstein S; Barnard KN; Anim M; Armoo A; Weichert WS; Bertozzi CR; Parrish CR; Willand-Charnley R
    Glycobiology; 2021 Nov; 31(10):1279-1294. PubMed ID: 34192335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.
    Gianchecchi E; Arena A; Fierabracci A
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
    Daly J; Carlsten M; O'Dwyer M
    Front Immunol; 2019; 10():1047. PubMed ID: 31143186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.